What was KRBPQ's price at the start of its 5-year chart?

Kiromic Biopharma IN (KRBPQ) opened at approximately $253.50 per share in 2021. The stock has returned -100.0% since then.

How many shares does KRBPQ have outstanding?

Kiromic Biopharma IN has approximately 2.7 million shares outstanding. At the current price, that puts the total market capitalization at $0M.

What is KRBPQ's market cap?

Kiromic Biopharma IN (KRBPQ) has a market capitalization of $0M, based on 2.7M shares outstanding at $0.00 per share.

What sector is KRBPQ in?

Kiromic Biopharma IN operates in the Health Care sector, in the Biotechnology industry, classified under Biotechnology.

How has KRBPQ performed over the past 5 years?

Since 2021, KRBPQ has returned -100.0% from its chart start price, underperforming the S&P 500 (SPY), which returned +70.5% over the same period.

What is KRBPQ's 5-year high?

KRBPQ's 5-year high was $330.00, reached in Jun 2021. The stock is currently 100.0% below that level.

What was KRBPQ's best year?

KRBPQ's best calendar year on record was 2026, when the stock returned +0.0%.

Market›Health Care›Biotechnology›Biotechnology

Kiromic Biopharma IN

KRBPQ

$0.00Apr 30, 2021 – Apr 29, 2026

Health CareBiotechnology$0M

MVM

+$0.0M

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan

Chart Start

$253.50

2021

Since 2021

-100.0%

vs SPY +70.5%

All-time High

$330.00 · Jun 2021

-100.0% from peak

MVM Rank

#193 of 594

Biotechnology

Reaction Win Rate

45%

14 of 31 events

Kiromic Biopharma IN has returned -100.0% from $253.50 since 2021, trailing SPY's +70.5% over the same period. The stock hit an all-time high of $330.00 in Jun 2021 and is currently 100.0% below that level. Of 31 tracked news events, 45% produced a positive market-adjusted return.

How to use this page

1Company Research Snapshot

Expand to read Wikipedia-sourced background on the company. Click any linked term to explore it inline — no page reload.

2Company Q&A

Common questions answered from real data: performance vs SPY, market cap, profitability, CEO, dividends, and more.

3News & Events

Every dot on the chart is a news event. The return shown is market-adjusted (vs SPY). Green = stock outperformed. Red = underperformed. Dot size = magnitude of reaction.

Company Q&AShow ▼

Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

Date	Return	Category	Source	Headline
2024-08-14	+107.4%	legal	Seeking Alpha	Kiromic stock soars 65% on FDA fast track status for Deltacel
2025-03-21	-85.0%	news	Investing.com	Kiromic Biopharma files for Chapter 7 bankruptcy - Investing.com
2023-09-13	-63.0%	news	Seeking Alpha	Kiromic BioPharma to list on OTC Pink Sheets after Nasdaq trading suspension
2023-03-10	-29.7%	news	Seeking Alpha	Kiromic BioPharma announces 1-for-30 reverse stock split
2022-10-06	+28.8%	earnings	Seeking Alpha	Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year
2021-06-30	-26.2%	news	Seeking Alpha	Kiromic BioPharma prices 8M share public offering; shares fall 21% after-hours
2021-05-24	+21.8%	news	Seeking Alpha	Kiromic submits IND for Iso-mesothelin gamma delta CAR T-cell therapy ahead of schedule
2024-04-10	+21.4%	news	Seeking Alpha	Kiromic BioPharma files to withdraw registration statement
2021-07-16	-20.1%	legal	Seeking Alpha	Kiromic BioPharma shares fall after FDA pushes back on INDs for CAR-T products
2022-02-03	-15.6%	executive	Seeking Alpha	Kiromic BioPharma appoints interim CEO
2023-02-28	-15.4%	news	GuruFocus	Scott Dahlbeck Net Worth (2026) - GuruFocus
2021-05-17	+15.3%	news	Seeking Alpha	Kiromic submits IND application for T-Cell therapy study in solid malignancies
2021-10-06	-14.5%	executive	Seeking Alpha	Kiromic BioPharma CFO Tony Tontat resigns, Daniel Clark named interim CFO
2022-05-13	-13.8%	earnings	Seeking Alpha	Kiromic BioPharma GAAP EPS of -$0.48
2021-05-14	+13.8%	earnings	Seeking Alpha	Kiromic BioPharma reports Q1 results
2021-06-07	+11.8%	executive	Seeking Alpha	Kiromic expands in-house cell therapy manufacturing facility, names new COO
2023-04-03	-8.6%	legal	Seeking Alpha	Kiromic stock pops on FDA filing to start trial of Deltacel for lung cancer
2021-08-13	-7.1%	earnings	Seeking Alpha	Kiromic BioPharma reports Q2 results
2025-01-21	-6.1%	news	Seeking Alpha	Kiromic files to raise $17M through uplisting
2022-05-11	-5.1%	news	Seeking Alpha	Kiromic BioPharma on plans to submit revised clinical trial application
2021-10-25	+5.1%	news	Seeking Alpha	Kiromic says cancer vaccine candidate led to seven-month progression free survival
2021-10-11	+5.1%	news	Seeking Alpha	Kiromic Bio forms alliance to analyze allogeneic CAR-T candidate in solid cancers
2021-07-27	+5.0%	M&A	Seeking Alpha	Kiromic finalizes acquisition of InSilico Solutions; shares surge 33% after-hours
2022-03-11	-4.5%	earnings	Seeking Alpha	Kiromic BioPharma GAAP EPS of -$0.40 misses by $0.14
2022-10-27	-4.3%	news	Seeking Alpha	Kiromic BioPharma arranges up to $10M financing
2023-02-16	-4.2%	earnings	Seeking Alpha	Kiromic BioPharma CEO encourages stock split, sees Deltacel trial in 2Q23
2021-07-02	-3.8%	news	Seeking Alpha	Kiromic closes equity offering, raises $40M
2022-04-08	+1.8%	earnings	Seeking Alpha	Kiromic BioPharma GAAP EPS of -$2.26
2022-07-12	+1.7%	executive	Seeking Alpha	Dr. Leonardo Mirandola is the new Chief Scientific Officer of Kiromic biopharma
2022-12-01	+1.7%	news	GuruFocus	Tony Tontat Net Worth (2026) - GuruFocus
2025-08-20	+0.7%	news	GuruFocus	Shannon Ralston Net Worth (2026) - GuruFocus

tickerdossier.com tickerdossier.substack.com